JPS6221359B2 - - Google Patents
Info
- Publication number
- JPS6221359B2 JPS6221359B2 JP55107363A JP10736380A JPS6221359B2 JP S6221359 B2 JPS6221359 B2 JP S6221359B2 JP 55107363 A JP55107363 A JP 55107363A JP 10736380 A JP10736380 A JP 10736380A JP S6221359 B2 JPS6221359 B2 JP S6221359B2
- Authority
- JP
- Japan
- Prior art keywords
- immunoglobulin
- fraction
- polyethylene glycol
- plasma
- fractionation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108060003951 Immunoglobulin Proteins 0.000 claims description 44
- 102000018358 immunoglobulin Human genes 0.000 claims description 44
- 238000005194 fractionation Methods 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 229920001223 polyethylene glycol Polymers 0.000 claims description 16
- 239000002202 Polyethylene glycol Substances 0.000 claims description 15
- 238000010306 acid treatment Methods 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 5
- 238000010253 intravenous injection Methods 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 238000011084 recovery Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 230000002391 anti-complement effect Effects 0.000 description 5
- 108010008730 anticomplement Proteins 0.000 description 5
- 102000057297 Pepsin A Human genes 0.000 description 4
- 108090000284 Pepsin A Proteins 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 229940111202 pepsin Drugs 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 229940012957 plasmin Drugs 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 108010068307 Alpha-Globulins Proteins 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035039 Piloerection Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000005371 pilomotor reflex Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- -1 that is Proteins 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10736380A JPS5732228A (en) | 1980-08-05 | 1980-08-05 | Preparation of immunoglobulin usable for intravenous injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10736380A JPS5732228A (en) | 1980-08-05 | 1980-08-05 | Preparation of immunoglobulin usable for intravenous injection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5732228A JPS5732228A (en) | 1982-02-20 |
| JPS6221359B2 true JPS6221359B2 (de) | 1987-05-12 |
Family
ID=14457176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10736380A Granted JPS5732228A (en) | 1980-08-05 | 1980-08-05 | Preparation of immunoglobulin usable for intravenous injection |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5732228A (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0168506B2 (de) * | 1984-07-07 | 1998-01-07 | Armour Pharma GmbH | Verfahren zur Herstellung von gamma-Globulin zur intravenösen Anwendung |
| JPH0662436B2 (ja) * | 1986-05-19 | 1994-08-17 | 株式会社ミドリ十字 | 静注用免疫グロブリン製剤の製造方法 |
| JPS6415785U (de) * | 1987-07-17 | 1989-01-26 | ||
| JP2775097B2 (ja) * | 1996-08-29 | 1998-07-09 | 株式会社ミドリ十字 | 静注用免疫グロブリン製剤 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4981519A (de) * | 1972-11-27 | 1974-08-06 | ||
| JPS5320415A (en) * | 1976-08-06 | 1978-02-24 | Coval M L | Production of gammaa globlin capaple of administering into vein and gammaagloblin produced by said method |
| JPS5372816A (en) * | 1976-12-03 | 1978-06-28 | Coval M L | Improved production of gammaaglobulin for vein injection |
-
1980
- 1980-08-05 JP JP10736380A patent/JPS5732228A/ja active Granted
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4981519A (de) * | 1972-11-27 | 1974-08-06 | ||
| JPS5320415A (en) * | 1976-08-06 | 1978-02-24 | Coval M L | Production of gammaa globlin capaple of administering into vein and gammaagloblin produced by said method |
| JPS5372816A (en) * | 1976-12-03 | 1978-06-28 | Coval M L | Improved production of gammaaglobulin for vein injection |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5732228A (en) | 1982-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4371520A (en) | Process for preparing immunoglobulin suitable for intravenous injection | |
| EP0073371B1 (de) | Intravenös injektierbares Globulin aus Immunserum und Verfahren zu seiner Herstellung | |
| FI60022B (fi) | Foerfarande foer framstaellning av rent intravenoesdugligt gammaglobulin | |
| US4276283A (en) | Method of preparing an intravenously administrable immune globulin preparation containing antibodies and preparations produced according to this method | |
| US4216205A (en) | Process of preparing a serum protein composition for intravenous application | |
| US5122373A (en) | Immunoglobulin-g-containing fraction | |
| JPH0348169B2 (de) | ||
| JP2547556B2 (ja) | ｒ−グロブリンの液状製剤 | |
| US3916026A (en) | Method for the preparation of gamma-globulin suitable for intravenous use | |
| KR960001473B1 (ko) | 정맥 주사용 면역글로불린 제제의 제조 방법 | |
| CA1137413A (en) | Method for the production of immunoglobulin having a high monomer content | |
| KR19980080440A (ko) | 면역글로불린 제제 및 이의 제조방법 | |
| US4322403A (en) | Method for the preparation of an immune globulin solution suitable for intravenous use | |
| JPH0365327B2 (de) | ||
| JPH0381290A (ja) | 精製されたアルブミン溶液の製造方法 | |
| JPS6136811B2 (de) | ||
| JPS5855432A (ja) | 静脈注射用免疫グロブリンの製法 | |
| JPS6221359B2 (de) | ||
| JPS6053009B2 (ja) | 肝炎ウイルスｂによる急性または慢性の感染治療用の新規医薬 | |
| US4886758A (en) | Method of determining incompatibility-reaction-causing substances in blood products as well as a method of inactivating said incompatibility-reaction-causing substances | |
| EP0078331B1 (de) | Verfahren zur Herstellung von intravenösem injizierbarem Immunoglobulin | |
| JP4003235B2 (ja) | 静注用免疫グロブリン製剤の製造方法 | |
| JP2672303B2 (ja) | 馬用感染予防治療剤 | |
| CA1172166A (en) | Process for preparing immunoglobulin suitable for intravenous injection | |
| KR860002096B1 (ko) | 정맥 주사에 적합한 면역 글로부린의 제조방법 |